Full-text search across primary regulatory records, analytical lab audits, and evidence-led pharmacology guides.
News WireOn August 12, 2026, Eli Lilly sued Aesthetic Envy, Astra, and four other entities over alleged illegal sales of its investigational obesity drug retatrutide. The company has referred over 200 entities to regulators and flagged 14,000.
News WireEli Lilly filed six federal lawsuits on August 12, 2026, against Aesthetic Envy, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. The complaints allege these businesses sold illegal versions of.
News WireForensic analysis of peptides sold through Facebook Marketplace and Australia Post revealed empty vials, wildly inconsistent dosing, and trace heavy metals. Australia's TGA responded by elevating unapproved peptides to a priority.
News WireThe FDA cleared oral semaglutide 25 mg as the first GLP-1 pill for weight loss on December 22, 2025. Truveta data shows the pill drew thousands of new patients into GLP-1 therapy. Eli Lilly's orforglipron awaits FDA review.
News WireThe drugmaker is suing four online peptide sellers, a California med spa, and a compounding pharmacy for marketing an unapproved triple-receptor agonist to consumers under a 'research use' label.
News WireEli Lilly filed six federal lawsuits against compounding pharmacies, med spas, and online sellers marketing unapproved retatrutide as 'research-use only,' challenging a labeling convention the drugmaker says conceals illegal human.